Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans

View Full Paper
Ask AI
Bookmark
Share

Authors

NHNoemi HummelALAlekhya Lavu

Discussion

Loading...

Member takes

Overview

Analysis estimates incidence and prevalence of polycythemia vera patients eligible for cytoreductive therapies, highlighting risk classifications across U.S. health plans.

Key Points

  • To estimate the number of polycythemia vera patients eligible for cytoreductive therapies per NCCN guidelines.
  • Systematic literature review to identify PV incidence and prevalence estimates.
  • Assessment of NCCN/ELN risk classifications distribution.
  • Data extraction from major U.S. commercial health plans' reports.
  • Mean incidence of 1.17 PV patients per 100,000 individuals identified.
  • Average of 37.3% of patients using cytoreductive therapy.
  • Significant variability in eligibility estimates across health plans.

Cite This Study

Hummel et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc32https://doi.org/10.1182/blood-2025-8202
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States2025
  2. 2Estimated prevalence of polycythemia vera in the United States (2025-2030): SEER analysis with modeled reporting delay.2026 · 1 citations
  3. 3Disparities and Trends in Polycythemia Vera–Related Mortality in U.S. Adults Aged ≥45 Years from 1999 to 20232025 · 6 citations
  4. 4Estimating incident and prevalent essential thrombocythemia patients eligible for cytoreductive therapies in the US and Canada2025
  5. 5Burden of illness in polycythemia vera: A retrospective medical chart audit study.2024 · 1 citations